Acute antihyperglycemic mechanisms of metformin in NIDDM

Evidence for suppression of lipid oxidation and hepatic glucose production

Gabriele Perriello, Paolo Misericordia, Elena Volpi, Antonella Santucci, Carla Santucci, Eleuterio Ferrannini, Mariarosa M. Ventura, Fausto Santeusanio, Paolo Brunetti, Geremia B. Bolli

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

To establish the antihyperglycemic mechanisms of metformin in non-insulin- dependent diabetes mellitus (NIDDM) independently of the long-term, aspecific effects of removal of glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose ~9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at the rate of 4 and 40 mU · m-2 · min-1) clamp combined with [3-3H]glucose infusion and indirect calorimetry, after administration of either metformin (500 mg per os, at -5 and -1 h before the clamp) or placebo. Compared with placebo, hepatic glucose production (HGP) decreased ~30% more after metformin (from 469 ± 50 to 330 ± 54 μmol/min), but glucose uptake did not increase. Metformin suppressed free fatty acids (FFAs) by ~17% (from 0.42 ± 0.04 to 0.35 ± 0.04 mM) and lipid oxidation by ~25% (from 4.5 ± 0.4 to 3.4 ± 0.4 μmol · kg-1 · min-1) and increased glucose oxidation by ~16% (from 16.2 ± 1.4 to 19.3 ± 1.3 μmol · kg-1 · min-1) compared with placebo (P < 0.05), but did not affect nonoxidative glucose metabolism, protein oxidation, or total energy expenditure. Suppression of FFA and lipid oxidation after metfomin correlated with suppression of HGP (r = 0.70 and r = 0.51, P < 0.001). The effects of metformin in obese and nonobese subjects were no different. We conclude that the specific, antihyperglycemic effects of metformin in the clinical condition of hyperglycemia in NIDDM are primarily due to suppression of HGP, not stimulation of glucose uptake, and are mediated, at least in part, by suppression of FFA and lipid oxidation.

Original languageEnglish (US)
Pages (from-to)920-928
Number of pages9
JournalDiabetes
Volume43
Issue number7
StatePublished - 1994
Externally publishedYes

Fingerprint

Metformin
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Lipids
Glucose
Liver
Nonesterified Fatty Acids
Placebos
Indirect Calorimetry
Hyperglycemia
Energy Metabolism
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Perriello, G., Misericordia, P., Volpi, E., Santucci, A., Santucci, C., Ferrannini, E., ... Bolli, G. B. (1994). Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes, 43(7), 920-928.

Acute antihyperglycemic mechanisms of metformin in NIDDM : Evidence for suppression of lipid oxidation and hepatic glucose production. / Perriello, Gabriele; Misericordia, Paolo; Volpi, Elena; Santucci, Antonella; Santucci, Carla; Ferrannini, Eleuterio; Ventura, Mariarosa M.; Santeusanio, Fausto; Brunetti, Paolo; Bolli, Geremia B.

In: Diabetes, Vol. 43, No. 7, 1994, p. 920-928.

Research output: Contribution to journalArticle

Perriello, G, Misericordia, P, Volpi, E, Santucci, A, Santucci, C, Ferrannini, E, Ventura, MM, Santeusanio, F, Brunetti, P & Bolli, GB 1994, 'Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production', Diabetes, vol. 43, no. 7, pp. 920-928.
Perriello, Gabriele ; Misericordia, Paolo ; Volpi, Elena ; Santucci, Antonella ; Santucci, Carla ; Ferrannini, Eleuterio ; Ventura, Mariarosa M. ; Santeusanio, Fausto ; Brunetti, Paolo ; Bolli, Geremia B. / Acute antihyperglycemic mechanisms of metformin in NIDDM : Evidence for suppression of lipid oxidation and hepatic glucose production. In: Diabetes. 1994 ; Vol. 43, No. 7. pp. 920-928.
@article{799cd505b6e04bbe8255b88ed56c34c0,
title = "Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production",
abstract = "To establish the antihyperglycemic mechanisms of metformin in non-insulin- dependent diabetes mellitus (NIDDM) independently of the long-term, aspecific effects of removal of glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose ~9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at the rate of 4 and 40 mU · m-2 · min-1) clamp combined with [3-3H]glucose infusion and indirect calorimetry, after administration of either metformin (500 mg per os, at -5 and -1 h before the clamp) or placebo. Compared with placebo, hepatic glucose production (HGP) decreased ~30{\%} more after metformin (from 469 ± 50 to 330 ± 54 μmol/min), but glucose uptake did not increase. Metformin suppressed free fatty acids (FFAs) by ~17{\%} (from 0.42 ± 0.04 to 0.35 ± 0.04 mM) and lipid oxidation by ~25{\%} (from 4.5 ± 0.4 to 3.4 ± 0.4 μmol · kg-1 · min-1) and increased glucose oxidation by ~16{\%} (from 16.2 ± 1.4 to 19.3 ± 1.3 μmol · kg-1 · min-1) compared with placebo (P < 0.05), but did not affect nonoxidative glucose metabolism, protein oxidation, or total energy expenditure. Suppression of FFA and lipid oxidation after metfomin correlated with suppression of HGP (r = 0.70 and r = 0.51, P < 0.001). The effects of metformin in obese and nonobese subjects were no different. We conclude that the specific, antihyperglycemic effects of metformin in the clinical condition of hyperglycemia in NIDDM are primarily due to suppression of HGP, not stimulation of glucose uptake, and are mediated, at least in part, by suppression of FFA and lipid oxidation.",
author = "Gabriele Perriello and Paolo Misericordia and Elena Volpi and Antonella Santucci and Carla Santucci and Eleuterio Ferrannini and Ventura, {Mariarosa M.} and Fausto Santeusanio and Paolo Brunetti and Bolli, {Geremia B.}",
year = "1994",
language = "English (US)",
volume = "43",
pages = "920--928",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Acute antihyperglycemic mechanisms of metformin in NIDDM

T2 - Evidence for suppression of lipid oxidation and hepatic glucose production

AU - Perriello, Gabriele

AU - Misericordia, Paolo

AU - Volpi, Elena

AU - Santucci, Antonella

AU - Santucci, Carla

AU - Ferrannini, Eleuterio

AU - Ventura, Mariarosa M.

AU - Santeusanio, Fausto

AU - Brunetti, Paolo

AU - Bolli, Geremia B.

PY - 1994

Y1 - 1994

N2 - To establish the antihyperglycemic mechanisms of metformin in non-insulin- dependent diabetes mellitus (NIDDM) independently of the long-term, aspecific effects of removal of glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose ~9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at the rate of 4 and 40 mU · m-2 · min-1) clamp combined with [3-3H]glucose infusion and indirect calorimetry, after administration of either metformin (500 mg per os, at -5 and -1 h before the clamp) or placebo. Compared with placebo, hepatic glucose production (HGP) decreased ~30% more after metformin (from 469 ± 50 to 330 ± 54 μmol/min), but glucose uptake did not increase. Metformin suppressed free fatty acids (FFAs) by ~17% (from 0.42 ± 0.04 to 0.35 ± 0.04 mM) and lipid oxidation by ~25% (from 4.5 ± 0.4 to 3.4 ± 0.4 μmol · kg-1 · min-1) and increased glucose oxidation by ~16% (from 16.2 ± 1.4 to 19.3 ± 1.3 μmol · kg-1 · min-1) compared with placebo (P < 0.05), but did not affect nonoxidative glucose metabolism, protein oxidation, or total energy expenditure. Suppression of FFA and lipid oxidation after metfomin correlated with suppression of HGP (r = 0.70 and r = 0.51, P < 0.001). The effects of metformin in obese and nonobese subjects were no different. We conclude that the specific, antihyperglycemic effects of metformin in the clinical condition of hyperglycemia in NIDDM are primarily due to suppression of HGP, not stimulation of glucose uptake, and are mediated, at least in part, by suppression of FFA and lipid oxidation.

AB - To establish the antihyperglycemic mechanisms of metformin in non-insulin- dependent diabetes mellitus (NIDDM) independently of the long-term, aspecific effects of removal of glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose ~9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at the rate of 4 and 40 mU · m-2 · min-1) clamp combined with [3-3H]glucose infusion and indirect calorimetry, after administration of either metformin (500 mg per os, at -5 and -1 h before the clamp) or placebo. Compared with placebo, hepatic glucose production (HGP) decreased ~30% more after metformin (from 469 ± 50 to 330 ± 54 μmol/min), but glucose uptake did not increase. Metformin suppressed free fatty acids (FFAs) by ~17% (from 0.42 ± 0.04 to 0.35 ± 0.04 mM) and lipid oxidation by ~25% (from 4.5 ± 0.4 to 3.4 ± 0.4 μmol · kg-1 · min-1) and increased glucose oxidation by ~16% (from 16.2 ± 1.4 to 19.3 ± 1.3 μmol · kg-1 · min-1) compared with placebo (P < 0.05), but did not affect nonoxidative glucose metabolism, protein oxidation, or total energy expenditure. Suppression of FFA and lipid oxidation after metfomin correlated with suppression of HGP (r = 0.70 and r = 0.51, P < 0.001). The effects of metformin in obese and nonobese subjects were no different. We conclude that the specific, antihyperglycemic effects of metformin in the clinical condition of hyperglycemia in NIDDM are primarily due to suppression of HGP, not stimulation of glucose uptake, and are mediated, at least in part, by suppression of FFA and lipid oxidation.

UR - http://www.scopus.com/inward/record.url?scp=0028342565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028342565&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 920

EP - 928

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -